American International Group, Inc. Outlook Therapeutics, Inc. Transaction History

American International Group, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$0.22 - $0.66 $168 - $504	764 Added 0.99%	78,175 $30,000
Q3 2023 Nov 13, 2023	BUY	$0.2 - $1.78 $550 - $4,898	2,752 Added 3.69%	77,411 $17,000
Q2 2023 Aug 04, 2023	BUY	$1.02 - $1.89 $18 - $34	18 Added 0.02%	74,659 $129,000
Q1 2023 May 12, 2023	BUY	$1.0 - $1.35 $18,608 - $25,120	18,608 Added 33.21%	74,641 $81,000
Q4 2022 Feb 10, 2023	SELL	$0.87 - $1.33 $177 - $271	-204 Reduced 0.36%	56,033 $60,000
Q3 2022 Nov 14, 2022	BUY	$1.02 - $1.26 $810 - $1,001	795 Added 1.43%	56,237 $69,000
Q2 2022 Aug 12, 2022	SELL	$0.91 - $2.01 $1,011 - $2,235	-1,112 Reduced 1.97%	55,442 $57,000
Q1 2022 May 13, 2022	BUY	$1.22 - $2.03 $11,254 - $18,726	9,225 Added 19.49%	56,554 $101,000
Q4 2021 Feb 11, 2022	SELL	$1.27 - $2.23 $1,799 - $3,159	-1,417 Reduced 2.91%	47,329 $64,000
Q3 2021 Nov 12, 2021	SELL	$2.12 - $2.76 $691 - $899	-326 Reduced 0.66%	48,746 $106,000
Q2 2021 Aug 13, 2021	BUY	$1.78 - $2.76 $87,348 - $135,438	49,072 New	49,072 $122,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.18B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.